Novartis India rallies for ninth session in a row, shares surge 74%; here is why

Shares of Novartis India, the country's leading drugmaker, advanced for a ninth straight session on Thursday, September 10. In nine trading sessions, Novartis India stock has surged as much as 74%, data from stock exchange showed.

In intraday deals on Thursday, Novartis India jumped as much as 18.28% to hit a record high of ₹2,588 on the BSE amid spike in trading activity.

Novartis India shares came under buying interest after the company presented its annual report for financial year 2025-26 in which it said that it plans to launch new products and in-license differentiated therapies in therapeutic “white spaces”.

The company added that it plans to take full commercial control of its key products such as Voveran, Methergin, Macalvit and Calcium Sandoz by bringing them under Novartis India's commercial control.

Novartis India said that its management plans to increase engagement with specialists and sharpen medical outreach, particularly around its established franchises.

The company added that it plans to deepen last-mile distribution in Tier-2 and Tier-3 cities, where some of its specialist franchises remain under-penetrated. Management sees this as a relatively direct way to increase volumes.

Earlier this week, Novartis India said that it will promote and execute Novartis Healthcare Private Limited's (NHPL) retina portfolio comprising the products Accentrix (Ranibizumab) and Pagenax (Brolucizumab) for the territory of India.

In a separate development, Novartis India’s board approved acquisition of trademarks ‘Minipress’ and ‘Minipres’ registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA for an aggregate consideration of ₹1,250 crore.

As per IQVIA MAT July 2026 data, Minipress XL recorded revenue of ₹228.6 crore and has been growing at a CAGR of 6.3% for past four years while the category has been growing at 9% CAGR for past four years.

Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH), Novartis India said.

Earlier this year in February, Novartis AG sold 1,74,50,680 shares representing 70.68% stake in the company. Acquirer 1 that is WaveRise Investments acquired 56.45% equity at ₹860.64 per share, while two other acquirers that is ChrysCapital Trust I and Two Infinity Partners acquired 10.32% and 3.91% stake respectively at ₹701.25 per share.

As of 2:45 pm, Novartis India shares traded 12% higher at ₹2,452, outperforming the NIFTY50 index which was trading on a flat note.